[Skip to Navigation]
Sign In
Invited Commentary
April 28, 2022

The ORATOR Trials Have Spoken—Where Do We Go From Here?

Author Affiliations
  • 1NYC Health and Hospitals, New York, New York
  • 2SUNY Downstate Medical School, New York, New York
  • 3Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas
JAMA Oncol. 2022;8(6):851-852. doi:10.1001/jamaoncol.2022.0461

In this issue of JAMA Oncology, Palma et al1 present ORATOR2, a prospective randomized clinical trial designed to test the best of nonsurgical and surgical deintensification strategies in low-risk human papillomavirus (HPV)–positive oropharynx squamous cell cancer (OPSCC). The results were published after deaths in the surgical arm led to early closure of the trial.

Add or change institution